BiotechTube

donepezil hydrochloride (Aricept)

ApprovedCompleted
2 views this week 0 watching⚡ Active
Interest: 43/100
43
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Vascular Dementia

Conditions

Vascular Dementia

Trial Timeline

Sep 1, 2005 → —

NCT ID
NCT00165763

About donepezil hydrochloride (Aricept)

donepezil hydrochloride (Aricept) is a approved stage product being developed by Eisai for Vascular Dementia. The current trial status is completed. This product is registered under clinical trial identifier NCT00165763. Target conditions include Vascular Dementia.

What happened to similar drugs?

20 of 20 similar drugs in Vascular Dementia were approved

Approved (20) Terminated (1) Active (0)
✅Rosuvamibe + MonorovaYuhanApproved
✅Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
✅Rosuvamibe + MonorovaYuhanApproved
✅Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
✅Lorcaserin hydrochloride + PlaceboEisaiApproved
✅Donepezil hydrochloride + Donepezil matching placebo + Donepezil hydrochlorideEisaiApproved
✅Empagliflozin + PlacebosEli LillyApproved

Hype Score Breakdown

Clinical
20
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT00675025Phase 2Terminated
NCT00711204ApprovedWithdrawn
NCT00165763ApprovedCompleted

Competing Products

20 competing products in Vascular Dementia

See all competitors
ProductCompanyStageHype Score
polypill + Usual cardiovascular medicationsDr. Reddy's LaboratoriesPhase 3
37
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
22
CLS-AX + AfliberceptClearside BiomedicalPhase 2
25
Eylea + ALT-L9AlteogenPhase 1
29
Dulaglutide + PlaceboEli LillyPhase 3
40
raloxifene + placeboEli LillyPhase 3
40
EvacetrapibEli LillyPhase 1
29
Orforglipron + PlaceboEli LillyPhase 3
47
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
25
Prasugrel (CS-747) + ClopidogrelEli LillyPhase 2
35
Rosuvamibe + MonorovaYuhanApproved
39
Efficacy and safety of combination therapy of moderate-intensity statin and ezetimibe compared to high-intensity statinYuhanApproved
43
Rosuvamibe + MonorovaYuhanApproved
43
olmesartanDaiichi SankyoPre-clinical
26
DS-7080a + RanibizumabDaiichi SankyoPhase 1
29
Prasugrel (Crushed tablets) + Prasugrel (Integral tablets)Daiichi SankyoApproved
43
Avacincaptad PegolAstellas PharmaPhase 1
29
Avacincaptad Pegol + Avastin + Lucentis + EyleaAstellas PharmaPhase 2
27
LexiscanAstellas PharmaPhase 2
35
YM872 (zonampanel)Astellas PharmaPhase 2
35